THE NEW YORK TIMES

Pfizer Gets $1.95 Billion to Produce Vaccine by Year’s End

THE NEW YORK TIMES

E.U. Agrees to $857 Billion Stimulus Deal

European Union leaders early on Tuesday stepped up to confront one of the gravest challenges in the bloc’s history, agreeing to a landmark spending package to rescue their economies from the ravages of the pandemic.

THE NEW YORK TIMES

Congress to Return With Stimulus Front and Center

Airlines, hotels and restaurants. Military contractors and banks. Even Broadway actors. These are just a few of the special interests already maneuvering to get a piece of the next coronavirus relief package about to be taken up by Congress, which is back in session this week.

THE NEW YORK TIMES

The U.S. shatters its daily case record for the 11th time in a month

As clashes over face-covering mandates and school reopening plans intensified throughout the United States, the country shattered its single-day record for new cases on Thursday — more than 75,600, according to a New York Times database.

THE NEW YORK TIMES

Russian Hackers Trying to Steal Vaccine Research, Intelligence Agencies Say

THE NEW YORK TIMES

A Resurgence of the Virus, and Lockdowns, Threatens Economic Recovery

WASHINGTON — The United States economy is headed for a tumultuous autumn, with the threat of closed schools, renewed government lockdowns, empty stadiums and an uncertain amount of federal support for businesses and unemployed workers all clouding hopes for a rapid rebound from recession.

Compartimos el número 549 de la revista América Latina en movimiento dedicada a la situación de pandemia que vivimos

THE NEW YORK TIMES

Why We’re Losing the Battle With Covid-19

The escalating crisis in Texas shows how the chronic underfunding of public health has put America on track for the worst coronavirus response in the developed world.

THE NEW YORK TIMES

Case numbers in the U.S. are rising in all but a handful of states.

THE NEW YORK TIMES

A Conservative Court and Trump’s Own Appointees Declare Their Independence

The Supreme Court’s dismissal of President Trump’s claims of immunity was a reminder that institutional prerogatives still matter in Washington, even in a time of extreme partisanship.